Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
By W. Winter, G. Maxwell, C. Tian, Jay Carlson, R. Ozols, P. Rose, M. Markman, D. Armstrong, F. Muggia, W. Mcguire. Journal of Clinical Oncology, 2007
858 citations recorded by the source corpus.
Subfields: Obstetrics and Gynecology, Oncology, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/db53ae2c69a4f9475e7bfc184f371b72e3ed45db
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Obstetrics and Gynecology
In Oncology
In Reproductive Medicine
Citations in the corpus
- Ovarian cancer development and metastasis. (2010, positive): “The surgical treatment goal is to remove as much tumor as possible, because several studies have convincingly shown that cytoreduction results in improved patient survival.(4,5) This effect of cytoreduction is indicative of a dramatic difference in the biological behavior of ovarian cancer as compar”
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials (2009, result): “However, we could not confirm, that the impact of complete debulking was only limited to better prognosis ovarian cancer as had been postulated by another European group.(15) Our results fit well with a recently reported observation of the GOG indicating a significant impact of complete tumor resect”
- Prognostic Significance of Tumor-infiltrating T-cells in Ovarian Cancer: a Meta-analysis (2011, background): “Prognosis is affected by patient factors, such as age or genetic background, as well as tumor characteristics, including stage, grade, histologic subtype, and chemotherapy sensitivity [1,2].”